Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes

被引:768
作者
Basta, G
Schmidt, AM
De Caterina, R
机构
[1] CNR, Inst Clin Physiol, I-56100 Pisa, Italy
[2] Columbia Univ, New York, NY USA
[3] Univ G DAnnunzio, Inst Cardiol, Osped S Camillo Lellis, I-66100 Chieti, Italy
[4] Univ G DAnnunzio, Ctr Excellence Aging, Osped S Camillo Lellis, I-66100 Chieti, Italy
关键词
advanced glycation end products; atherosclerosis; inflammation; diabetes; endothelium;
D O I
10.1016/j.cardiores.2004.05.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The formation of advanced glycation end products (AGEs) is an important biochemical abnormality that accompanies diabetes mellitus, and, likely, inflammation in general. Here we summarize and discuss recent studies indicating that the effects of AGEs on vessel wall homeostasis may account for the rapidly progressive atherosclerosis associated with diabetes mellitus. Driven by hyperglycemia and oxidant stress, AGEs form to a greatly accelerated degree in diabetes. Within the vessel wall, collagen-linked AGEs may "trap" plasma proteins, quench nitric oxide (NO) activity and interact with specific receptors to modulate a large number of cellular properties. On plasma low density lipoproteins (LDL), AGEs initiate oxidative reactions that promote the formation of oxidized LDL. Interaction of AGEs with endothelial cells, as well as with other cells accumulating within the atherosclerotic plaque, such as mononuclear phagocytes and smooth muscle cells (SMCs), provides a mechanism to augment vascular dysfunction. Specifically, the interaction of AGEs with vessel wall components increases vascular permeability, the expression of procoagutant activity and the generation of reactive oxygen species (ROS), resulting in increased endothelial expression of endothelial leukocyte adhesion molecules. AGEs potently modulate initiating steps in atherogenesis involving blood-vessel wall interactions, triggering an inflammatory-proliferative process and, furthermore, critically contribute to propagation of inflammation and vascular perturbation in established disease. Thus, a better understanding of the biochemical mechanisms by which AGEs contribute to such processes in the vessel wall could be relevant to devise preventive and therapeutic strategies for diabetic atherosclerosis. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:582 / 592
页数:11
相关论文
共 98 条
  • [1] Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein - A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation
    Anderson, MM
    Hazen, SL
    Hsu, FF
    Heinecke, JW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (03) : 424 - 432
  • [2] Advanced glycation end products activate endothelium through signal-transduction receptor RAGE - A mechanism for amplification of inflammatory responses
    Basta, G
    Lazzerini, G
    Massaro, M
    Simoncini, T
    Tanganelli, P
    Fu, CF
    Kislinger, T
    Stern, DM
    Schmidt, AM
    De Caterina, R
    [J]. CIRCULATION, 2002, 105 (07) : 816 - 822
  • [3] Diabetes-associated sustained activation of the transcription factor nuclear factor-κB
    Bierhaus, A
    Schiekofer, S
    Schwaninger, M
    Andrassy, M
    Humpert, PM
    Chen, J
    Hong, M
    Luther, T
    Henle, T
    Klöting, I
    Morcos, M
    Hofmann, M
    Tritschler, H
    Weigle, B
    Kasper, M
    Smith, M
    Perry, G
    Schmidt, AM
    Stern, DM
    Häring, HU
    Schleicher, E
    Nawroth, PP
    [J]. DIABETES, 2001, 50 (12) : 2792 - 2808
  • [4] Advanced glycation end product-induced activation of NF-kappa B is suppressed by alpha-lipoic acid in cultured endothelial cells
    Bierhaus, A
    Chevion, S
    Chevion, M
    Hofmann, M
    Quehenberger, P
    Illmer, T
    Luther, T
    Berentshtein, E
    Tritschler, H
    Muller, M
    Wahl, P
    Ziegler, R
    Nawroth, PP
    [J]. DIABETES, 1997, 46 (09) : 1481 - 1490
  • [5] Bierhaus A, 1997, CIRCULATION, V96, P2262
  • [6] BRETT J, 1993, AM J PATHOL, V143, P1699
  • [7] AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING
    BROWNLEE, M
    VLASSARA, H
    KOONEY, A
    ULRICH, P
    CERAMI, A
    [J]. SCIENCE, 1986, 232 (4758) : 1629 - 1632
  • [8] BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
  • [9] IDENTIFICATION OF THE MAJOR SITE OF APOLIPOPROTEIN-B MODIFICATION BY ADVANCED GLYCOSYLATION END-PRODUCTS BLOCKING UPTAKE BY THE LOW-DENSITY-LIPOPROTEIN RECEPTOR
    BUCALA, R
    MITCHELL, R
    ARNOLD, K
    INNERARITY, T
    VLASSARA, H
    CERAMI, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (18) : 10828 - 10832
  • [10] MODIFICATION OF LOW-DENSITY-LIPOPROTEIN BY ADVANCED GLYCATION END-PRODUCTS CONTRIBUTES TO THE DYSLIPIDEMIA OF DIABETES AND RENAL-INSUFFICIENCY
    BUCALA, R
    MAKITA, Z
    VEGA, G
    GRUNDY, S
    KOSCHINSKY, T
    CERAMI, A
    VLASSARA, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) : 9441 - 9445